Leigongteng Duoganpian

Shop Now

Overview

What is Leigongteng Duoganpian?

Leigongteng Duoganpian is a single-ingredient proprietary Traditional Chinese Medicine (TCM) preparation made from Tripterygium wilfordii glycosides, primarily used to manage rheumatoid arthritis and selected immune-mediated inflammatory disorders.

Rheumatoid arthritis, nephrotic syndrome, Behçet syndrome, leprosy reactions, and autoimmune hepatitis. Use only under medical supervision.

Product Information

Chinese name雷公藤多苷片
Alternative NameLei Gong Teng Duo Gan Pian/Tripterygium Glycosides Tablet
BrandFeiyun
Manufacturer远大医药黄石飞云制药有限公司
China Drug Approval No.Z42021212
Dosage formtablet
Strength10 mg
Individual package10 mg × 100 tablets
GTIN6921329400316
Prescription Status in ChinaPrescription medicine.

Ingredients

Leigongteng Duoganpian is made from 1 herb: Tripterygium Glycosides (Lei Gong Teng Duo Gan).

Benefits & Uses

Benefits & Common Uses

Tripterygium Glycosides Tablets is commonly used for:

  • Rheumatoid arthritis
  • Nephrotic syndrome
  • Behçet syndrome
  • Leprosy reactions
  • Autoimmune hepatitis

How It Works

Modern research has investigated bioactive constituents in several ingredients in the Leigongteng Duoganpian formula, providing insight into biological activities that may help explain aspects of its traditional use.

  • Tripterygium Glycosides (Lei Gong Teng Duo Gan)

    Modern research on Tripterygium Glycosides has focused particularly on its preparation as a multi-component root extract, with experimental studies examining chemical composition, manufacturing variation, and in vitro biological activity.

Traditional Functions & Uses

祛风解毒、除湿消肿、舒筋通络

Dispels wind and detoxifies, removes dampness and swelling, and relaxes the sinews and unblocks the collaterals.

Leigongteng Duoganpian is classified as a prescription medicine in China. This Learn information is for educational purposes only. Always consult a healthcare provider before starting TCM treatments.

Safety

Adverse Reactions

  • Gastrointestinal symptoms; liver injury; reduced white blood cells or platelets; kidney effects; menstrual or sperm changes; rash and hair loss.

Contraindications

  • Do not use in children, during pregnancy or breastfeeding, or when pregnancy is desired.
  • The label also contraindicates use with cardiac, liver, or kidney insufficiency; severe anemia or low white blood cell or platelet counts; active peptic ulcer; or severe arrhythmia.

Precautions

Use only under medical supervision at the labeled dose. The label calls for follow-up tests of blood, urine, ECG, and liver and kidney function, and says continuous use generally should not exceed three months unless a clinician decides otherwise.

Evidence

Evidence at a Glance

Available human evidence concerns rheumatoid arthritis. A 2021 guideline addresses Tripterygium Glycosides and Tripterygium wilfordii tablets using clinical research, expert consensus, and experience. A 2022 meta-analysis of 38 trials evaluated Tripterygium glycosides added to conventional DMARDs. The combination findings cannot be attributed to Tripterygium glycosides alone; variation in treatment course and background DMARDs, together with risk of bias, limits certainty.

  • Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis

    Design: Clinical Practice Guideline

    Year: 2021

    The guideline summarizes indications, dosage, combined medication, and safety for TGT and TWT in rheumatoid arthritis. It describes oral TGT dosing by body weight in divided doses after meals.

    Population: People with rheumatoid arthritis; recommendations address Tripterygium Glycosides Tablets and Tripterygium wilfordii Tablets.

    Indication: Rheumatoid arthritis

    Intervention: Tripterygium Glycosides Tablets (TGT) and Tripterygium wilfordii Tablets (TWT)

    Comparison: Recommendations synthesized clinical research evidence, expert consensus, and experience; not a single controlled comparison.

    Reported findings

    The guideline summarizes indications, dosage, combined medication, and safety for TGT and TWT in rheumatoid arthritis. It describes oral TGT dosing by body weight in divided doses after meals.

    Interpretation

    This document summarizes recommendations for TGT and TWT using clinical evidence and consensus; it is not a single controlled trial.

    Limitations

    The document combines evidence-based recommendations with expert consensus and experience. It addresses both TGT and TWT, and does not establish that the exact 10 mg × 100 commercial package was studied.

    Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis. PMID:33519474. DOI:10.3389/fphar.2020.608703.

    Authors: Na Lin, Yan-Qiong Zhang, Quan Jiang, et al.

    Journal: Frontiers in Pharmacology

    Year: 2021

    Study type: Other

    PMID: 33519474

    DOI: 10.3389/fphar.2020.608703

  • Efficacy of tripterygium glycosides (TG) in rheumatoid arthritis as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional DMARDs: A systematic review and meta-analysis of randomized controlled trials

    Design: Systematic Review And Meta-analysis

    Year: 2022

    The review included 38 randomized controlled trials and reported differences in disease activity and inflammatory measures for regimens combining tripterygium glycosides with conventional DMARDs compared with conventional DMARD regimens.

    Population: People with rheumatoid arthritis in randomized trials of tripterygium glycosides with conventional DMARDs.

    Indication: Rheumatoid arthritis

    Intervention: Tripterygium glycosides combined with one conventional DMARD, including methotrexate, leflunomide, or hydroxychloroquine in included studies.

    Comparison: Combined TG regimens compared with conventional DMARD monotherapy.

    Duration: Varied across included trials.

    Reported findings

    The review included 38 randomized controlled trials and reported differences in disease activity and inflammatory measures for regimens combining tripterygium glycosides with conventional DMARDs compared with conventional DMARD regimens.

    Interpretation

    Those findings are specific to the added combination regimens and cannot be assigned to tripterygium glycosides as a stand-alone treatment.

    Limitations

    The source identifies risk of bias and variation in age, treatment course, and combined DMARD type as factors influencing the findings. The abstract does not report manufacturers, approval numbers, or retail package details.

    Efficacy of tripterygium glycosides (TG) in rheumatoid arthritis as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional DMARDs: A systematic review and meta-analysis of randomized controlled trials. PMID:36028187. DOI:10.1016/j.phrs.2022.106405.

    Authors: Zhe Feng, Ling Fu, Junqin Wang, et al.

    Journal: Pharmacological Research

    Study type: Meta Analysis

    PMID: 36028187

    DOI: 10.1016/j.phrs.2022.106405

Verification

Verified by the AuthHerb Verification Team
  • Brand relationship confirmed
  • Manufacturer legal name confirmed
  • Approval number confirmed
  • Current packaging matched
  • Registration holder / manufacturer checked
  • Authenticity method checked
  • Label/source evidence recorded

Official Label Dosage

Take orally at 1–1.5 mg per kg of body weight daily in three divided doses after meals, or as directed by a clinician.

A purchase option’s quantity does not define how long you should take the medicine.